Audit: QRS - Intermittent Hypoxia-Hyperoxia for Health & Longevity

Audit conducted on 30/08/2026 03:32 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Protocol cells trace to ER lines 390–394; time-to-effect to ER line 447; benefits/risks to the ER tier headings; monitoring rows to the ER biomarker table (ER lines 481–492); cadence to ER line 477.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The one hedged value, RMSSD “No established population target”, is carried over verbatim (QRS line 787 vs ER line 491).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	All 14 ER avoidance populations remain absolute contraindications; the ER’s “Absolute contraindication” for erythropoiesis-stimulating agents is placed in the stop gate, not the caution gate.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Nothing from the ER Benefit- or Risk-Modifying Factors sections appears in the gates; gates draw only on ER Key Interactions & Contraindications.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT identifiers, author names, or device brands (ReOxy, CellGym, OxyTerra) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind in the QRS body.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Neutral, measured register matching the ER; “the findings that hold up” mirrors the ER Conclusion’s framing.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits/risks and quantified monitoring targets carry the data; the At-A-Glance separates what holds up from what does not.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring cells state what trials and practitioners do; no imperatives directed at a reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “must”, “recommended”, or “advised” anywhere in the rendered content.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Descriptive phrasing throughout, e.g. “Each hypoxic block ends on the saturation reading, not the clock”.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns present.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are confined to the biomarker table and contraindication gate where they are ER-verbatim and necessary; the At-A-Glance is jargon-free.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate, benefit, and risk entry is a bare noun phrase with no elaboration.
2.9	It DOES NOT address the reader directly	🟢	Confirmed by scan for second-person forms; none found.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes willingness to undertake a supervised device-delivered course and a full baseline blood panel.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	A 10–15 session clinic course and 12-marker monitoring panel are presented without hedging on burden.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification toward casual use; functional biomarker ranges rather than conventional cut-offs are given.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance separates the durable findings from the weak ones and flags that ageing claims rest on cell and animal work.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“Longevity” in the title and header; “ageing” used descriptively; no “anti-aging” anywhere.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Low-density lipoprotein cholesterol”, “haematocrit”, “symptomatic” register held throughout; no consumer-grade substitutions.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All verified at QRS lines 446, 489, 531, 564, 586, 609, 637, 641–643, 824; tier labels at lines 535, 541, 547, 554, 612, 616, 622, 628.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Diff of the extracted variable name sets shows every template variable present; the repeatable marker_#_* and qualitative_item_# spans are expanded to 12 and 6 instances respectively.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	The website="evidence_review", website="audit" and website="full_review" spans, the footer disclaimer and all CSS are byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section mapped by this QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard session structure”, “Standard course”, “Target saturation, not fixed timing” match the ER bold labels at ER lines 390, 392, 394 verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol labels are ER-verbatim; monitoring row labels match the ER Biomarker column exactly.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	Unicode scan returns no emoji; the ER’s “⚠️ Conflicted” markers are correctly stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Per-section condensation is applied throughout: gate items are bare noun phrases with qualifiers reduced to symbols (e.g. “≥180/110 mmHg”, “≥15 events/hour”), benefit and risk tiers are collapsed to single semicolon-separated lines, and qualitative items are trimmed of the ER’s illustrative clauses.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment spanning QRS lines 2–14, immediately after the doctype at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13; the preceding title text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, body or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: intermittent_hypoxia_hyperoxia_2026-0830-0012_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0830-0311, correct format.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All nine keys carry trimmed values; quoting used only where YAML requires it.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Intermittent Hypoxia-Hyperoxia for Health & Longevity - Quick Reference Sheet”, matching ER canonical_topic with the ampersand encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417 carries the canonical topic with &.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “08/30/2026”, the correct reformat of 2026-0830-0311.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the template subline; the ER’s seven alternate names are not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 523 and 527 into delivery format, the findings that hold, and the ones that do not.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Delivery mode from ER line 37/523; the three durable findings from ER line 523; the weak-signal list and the cell/animal caveat from the same passage.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “blood sugar”, “thinking”, “cell and animal work” used in place of the ER’s clinical register.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric results of any kind.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All 15 entries trace to ER lines 339 and 355–368.
8.2	[stop_items] represent the Contraindications from the ER	🟢	The ER’s 14 avoidance populations plus erythropoiesis-stimulating agents, which the ER labels “Absolute contraindication” at line 339.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	15 <li> elements at QRS lines 567–581.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No trailing clauses; the only en-dash is the range inside “class III–IV”. The ER’s mechanistic rationale for the ESA contraindication (“Additive stimulation of red-cell production risks excessive haematocrit and thrombosis”) is stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within 90 days”, “within 6 months”, “class III–IV”, “(≥180/110 mmHg)”, “any functional class”, “below 92%”, “above 52%”, “(≥15 events/hour)”, “less than 5 years” all retained in compressed form.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its contraindication list.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names 14 avoidance populations plus an absolute drug contraindication, and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All nine entries trace to ER lines 333–351.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Nine of the ER’s ten interaction bullets are carried; erythropoiesis-stimulating agents are correctly excluded here and placed in the stop gate.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Nine <li> elements at QRS lines 589–599.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s “Caution/Monitor” verdicts, mechanisms and mitigations are all stripped; no trailing dash clauses remain.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Named examples preserved for every bullet that carries them: amlodipine/lisinopril/losartan/bisoprolol, furosemide/hydrochlorothiazide, insulin/gliclazide, diphenhydramine, beetroot nitrate/L-Citrulline/L-Arginine, magnesium/potassium/omega-3/hibiscus/garlic.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation in its interaction bullets.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names ten interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 390–394.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Session structure, course length, and the saturation-target rule are the ER’s first three bullets and the only ones that specify what is actually done; the remaining ER bullets are competing approaches and population caveats.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine cells populated; values and subs carry the ER’s numeric parameters (3–5 cycles, 24–40 min, 10–14%, 30–40%, 10–15 sessions, 80–85% nadir).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Blood pressure/autonomic, walking capacity and cognition are the only outcomes for which the ER states a time to effect (ER line 447).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Blood pressure and functional exercise capacity are ER High-tier benefits and occupy slots 1 and 2; cognitive screening is a Medium-tier benefit and occupies slot 3.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine cells populated; “Single session”, “5–7 weeks” and the qualifier “Measured only at five to seven weeks” match ER line 447 including its “nothing shorter has demonstrated them” caveat.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides time-to-effect information at line 447, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All 13 entries map one-to-one onto the ER’s benefit headings at lines 153–237.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at QRS lines 533, 539, 545, 552, matching the ER’s four tiers.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER heading alone; every Magnitude line, mechanism sentence and trial description is dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits span; the ER’s “⚠️ Conflicted” markers are also removed.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER benefit tiers contain items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All eight entries map one-to-one onto the ER’s risk headings at lines 263–311.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at QRS lines 611, 614, 620, 626, matching the ER’s four tiers.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each entry is the ER heading alone; the ER’s adverse-event counts (95 events across 20 participants) and effect sizes are dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks span; the “⚠️ Conflicted” marker on the haemoglobin/haematocrit item is removed.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence derive from ER Monitoring Protocol & Defining Success, lines 475–492.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 12 ER table rows present in ER order — SpO₂, haemoglobin, haematocrit, ferritin, hs-CRP, HbA1c, fasting glucose, LDL-C, ApoB, seated blood pressure, RMSSD, ALT — with targets and reasons carried verbatim.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	QRS lines 814–818 reproduce the ER’s two-track cadence from line 477, including the complete-blood-count escalation trigger.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six entries derive from the ER’s qualitative-marker list at lines 496–501.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER items present: energy/fatigue, breathlessness on familiar exertion, sleep onset latency and night-waking, cognitive clarity and word-finding, post-session headache/dizziness/flushing, and exercise recovery.

Issues 30/08/2026 03:32

Pass rate 100.00%. No issues found.

Issues 30/08/2026 03:25

1. 2.15 — Colloquial “bloods” in cadence: The monitoring cadence at line 815 says “bloods at 6 weeks, 3 months”; the ER’s own voice is “Blood testing repeats at 6 weeks, then at 3 months” (ER line 477).
2. 1.3 — Asthma contraindication narrowed: Contraindication line 573 reads “uncontrolled asthma” where the ER (line 361) excludes “poorly controlled asthma”, softening the gate to a narrower population.

Fixes 30/08/2026 03:25

1. 2.15 — Colloquial “bloods” replaced: Monitoring cadence now reads “blood testing at 6 weeks, 3 months” instead of “bloods at 6 weeks, 3 months”, matching the ER’s formal wording.
2. 1.3 — Asthma contraindication restored: Changed “uncontrolled asthma” to “poorly controlled asthma” so the gate covers the same population the ER excludes.

Issues 30/08/2026 03:17

1. 4.5 — Exceeds one-page A4 budget: Content volume runs to roughly two A4 pages: a 15-item contraindication gate with eight two-line wraps, a 12-row monitoring table, and long action_#_sub / time_#_sub / qualitative_item_# strings that each wrap to two or three lines.
2. 2.8 — Elaboration instead of key fact: time_2_sub and time_3_sub (lines 514–531) repeat the same 14-word sentence with one noun changed, and five of six qualitative_item_* spans (lines 839–872) append rationale clauses rather than naming the marker.

Fixes 30/08/2026 03:17

1. 4.5 / 2.8 — Duplicated time-to-effect subs: Replaced the two near-identical 14-word time_2_sub and time_3_sub sentences with “Measured only at five to seven weeks”, and trimmed time_1_sub from “Appear after one session and consolidate over three weeks” to “Consolidate over three weeks” since the value cell already states “Single session”.
2. 4.5 / 2.8 — Qualitative items carried rationale: Stripped the trailing explanatory clauses from all six qualitative_item_* spans, leaving the marker itself (e.g. “Sleep onset latency and night-waking frequency”, “Cognitive clarity and word-finding”).
3. 4.5 — Protocol sub cells condensed: Shortened action_1_sub to “5 min at 10–14% inspired oxygen alternating with 3 min at 30–40%”, action_2_sub to “On weekdays, or 3 weekly over 6 weeks in geriatric trials”, and action_3_sub to “Each hypoxic block ends on the saturation reading, not the clock”, each now fitting a single line.
4. 4.5 / 8.4 — Contraindication gate wrapping: Condensed eight two-line stop items to one line each while preserving every threshold and time window — e.g. “Uncontrolled hypertension (≥180/110 mmHg)”, “Untreated moderate-to-severe sleep apnoea (≥15 events/hour)”, “Unstable angina, or class III–IV stable angina”. All 15 items are retained.
5. 4.5 / 9.4 — Key Interactions gate wrapping: Reduced “Supplements with additive blood-pressure lowering (magnesium, potassium, omega-3 fatty acids, hibiscus, garlic extract)” to “Blood-pressure-lowering supplements (magnesium, potassium, omega-3, hibiscus, garlic)” and dropped the redundant “Over-the-counter” prefix from the sedating-antihistamine item.
6. 4.5 — Monitoring cadence condensed: Tightened monitoring_cadence from “blood testing repeats at 6 weeks, then at 3 months, then every 6 to 12 months if courses are repeated” to “bloods at 6 weeks, 3 months, then every 6–12 months if courses repeat”, keeping the complete-blood-count escalation trigger.